The time of day of immunotherapy infusions does appear to affect patient outcomes. But convincing the wider oncology community may be a hard...

DONGGUAN, China, Feb. 28, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins...

Patients receiving an immune checkpoint inhibitor for a neoplasm face an increased risk for rheumatoid arthritis, an observational study fou...

A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing cancer treatment....

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with chemoradiothera...

First patient treated in the U.S. Initial enrollment planned for the U.S., Japan, and Taiwan, with further expansion to additional countries...

Experts said Durvalumab could be a ‘game changer’

SAN FRANCISCO, Jan. 2, 2025 /PRNewswire/ -- Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, will pre...

Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S. Phase 1 trial is progressing...

Should patients with TNBC who did not receive immunotherapy before surgery get it after, if they have residual disease? Experts explore the...

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the adjuvant setting....

ARCADIA, Calif., Nov. 11, 2024 /PRNewswire/ -- Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapie...

Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving p...

Studies Selected for Presentation at Global Gathering FORT MYERS, Fla., Nov. 7, 2024 /PRNewswire/ -- Clinical research conducted with partic...